[Evaluation of the therapeutic efficacy of vastarel 20 mg (trimetazidine) in cochleovestibular syndromes. A double-blind study versus placebo].
334 patients with functional cochleovestibular symptomatology were treated with trimetazidine (40 mg daily) or with placebo in a double-blind study. The decrease in subjective symptoms (tinnitus, hypoacusis, vertigo, disturbances of equilibrium, neurovegetative disturbances, bad discrimination in background noise) was significantly more important with trimetazidine than with placebo. Objective signs such as index deviation, walking tests and positive Romberg test were also significantly more improved with trimetazidine. Puretone audiometry in patients with perceptive hypoacusis showed an improvement of auditory level with trimetazidine; progression with trimetazidine is significantly better than that with placebo, at frequencies equal to or above 2 000 Hz. Overall and cardiovascular clinical acceptability is similar in both groups. This study underlines the therapeutic efficacy of trimetazidine in cochleovestibular syndromes, especially on functional symptomatology.
D000328:Adult; D001299:Audiometry; D002986:Clinical Trials as Topic; D003051:Cochlea; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007759:Labyrinth Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos; D011897:Random Allocation; D014292:Trimetazidine / Q000627:therapeutic use*; D014724:Vestibular Function Tests; D014722:Vestibule, Labyrinth
D010879:Piperazines; D010919:Placebos; D014292:Trimetazidine
Evaluation de l'efficacité thérapeutique de vastarel 20 mg (trimétazidine) au cours des syndromes cochléo-vestibulaires. Etude à double insu contre placebo.